Constitutive overexpression of cyclin D1 in human breast epithelial cells does not prevent G1 arrest induced by deprivation of epidermal growth factor

Breast Cancer Research and Treatment

Volumn 55, Issue 3, 1999, Pages 267-283

  Chou, Jia Ling ^a   Fan, Zhen ^b   DeBlasio, Tony ^a   Koff, Andrew ^a   Rosen, Neal ^a   Mendelsohn, John ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Cyclin D1; Egf deprivation; G1 arrest

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE; EPIDERMAL GROWTH FACTOR; PHOSPHOTRANSFERASE; PROTEIN P27;

ARTICLE; BREAST EPITHELIUM; CELL CYCLE G1 PHASE; CELL GROWTH; COLONY FORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION;

ANTIBODIES, MONOCLONAL; BREAST; CDC2-CDC28 KINASES; CELL CYCLE; CELL CYCLE PROTEINS; CELL DIVISION; CELL LINE; CYCLIN D1; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; CYCLINS; EPIDERMAL GROWTH FACTOR; EPITHELIAL CELLS; G1 PHASE; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEINS;

EID: 0032867174     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006217413089     Document Type: Article

References (72)

1. Ennis BW, Valverius EM, Lippman EM, Bellot F, Kris R, Schlessinger J, Masui H, Goldenberg A, Mendelsohn J, Dickson RB: Monoclonal anti-EGF receptor antibodies inhibit the growth of malignant and nonmalignant human mammary epithelial cells. Mol Endocrinol 3: 1830-1838, 1989.
2. Sato JD, Kawamoto T, Le A, Mendelsohn J, Polikoff J, Sato GH: Biological effect in vitro of monoclonal antibodies to human EGF receptors. Mol Biol Med 1: 511-529, 1983
3. Stampfer MR, Pan CH, Hosoda J, Bartholomew J, Mendelsohn J, Yaswen P: Blockage of EGF receptor signal transduction causes reversible arrest of normal and immortal human mammary epithelial cells with synchronous reentry into the cell cycle. Exp Cell Res 208: 175-188, 1993
4. Artega CL, Coronado E, Osborne CK: Blockade of the epidermal growth factor receptor inhibits transforming growth factor α-induced but not estrogen-induced growth of hormone-dependent human breast cancer. Mol Endocrinol 2: 1064-1069, 1988
5. Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Cordon-Cardo C, Miller W, Mendelsohn J: Anti-tumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 85: 1327-1331, 1993
6. Reiss M, Stash EB, Vellucci VE, Zhou Z: Activation of the autocrine transforming growth factor alpha pathway in human squamous carcinoma cells. Cancer Res 51: 6254-6262, 1991
7. Atlas I, Mendelshon J, Baselga J, Fair WR, Masui H, Kumar R: Growth regulation of human renal carcinoma cells: Role of transforming growth factor alpha. Cancer Res 52: 3335-3339, 1992
8. Masui H, Boman B, Hyman J, Castro L, Mendelsohn J: Treatment with anti-EGF receptor monoclonal antibody causes regression of DiFi human colorectal carcinoma xenografts (Abstract). Proc Am Assoc Cancer Res 32: 394, 1991
9. Karnes WE, Jr., Walsh JH, Wu SV, Kim RS, Martin MG, Wong HC, Mendelsohn J, Gazdar AF, Cuttitta F: Autonomous proliferation of colon cancer cells that coexpress transforming growth factor alpha and its receptor: Variable effects of receptor-blocking antibody. Gastroenterology 102: 474-485, 1992
10. Kawamoto T, Mendelsohn J, Le A, Sato G, Lazar CS, Gill GN: Relation of epidermal growth factor receptor concentration to growth of human epidermoid carcinoma A431 cells. J Biol Chem 259: 7761-7766, 1984
11. Fan Z, Baselga J, Masui H, Mendelsohn J: Antitumor effect of anti-EGF receptor monoclonal antibodies plus cis-Diamminodichloroplatinum (cis-DDP) on well established A431 cells xenografts. Cancer Res 53: 4637-4642, 1993
12. Hofer DR, Sherwood ER, Bromberg WD, Mendelsohn J, Lee C, Kozlowski JM: Autonomous growth of androgen-independent human prostatic carcinoma cells: Role of transforming growth factor alpha. Cancer Res 51: 2780-2785, 1991
13. Gill GN, Kawamoto T, Cochet C, Le A, Sato JD, Masui H, MacLeod CL, Mendelsohn J: Monoclonal anti-epidermal growth factor receptor antibodies which arc inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem 259: 7755-7760, (1984)
14. Kawamoto T, Sato JD, Le A, Polikoff J, Sato GH, Mendelsohn J: Growth stimulation of A431 cells by EGF: Identification of high affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci USA 80: 1337-1341, 1983
15. Mendelsohn J, Masui H, Goldenberg A: Anti-epidermal growth factor receptor monoclonal antibodies may inhibit A431 tumor cell proliferation by blocking on autocrine pathway. Trans Assoc Am Phys 100: 173-178, 1987
16. Van de Vijver MJ, Kumar R, Mendelsohn J: Ligand-induced activation of A431 cell epidermal growth factor receptors occurs primarily by an autocrine pathway that acts upon receptors on the surface rather than intracellularly. J Biol Chem 266:7503-7508, 1991
17. 1 cyclins. Cell 73: 1059-1065, 1993
18. Hunter T, Pines J: Cyclins and cancer II: Cyclin D and CDK inhibitors come of age. Cell 79:573-582, 1994
19. Morgan D: Principles of CDK regulation. Nature 374: 131-134, 1995
20. Matsushime H, Quelle ED, Shurtleff SA, Shibuya M, Sherr CJ, Kato JY: D-type cyclin-dependent kinase activity in mammalian cells. Mol Cell Biol 14: 2066-2076, 1994
21. Xiong Y, Zhang H, Beach D: D-type cyclins associated with multiple protein kinases and the DNA replication and repair factor PCNA. Cell 71: 505-514, 1992
22. Koff A, Cross F, Fisher A, Schumacher J, Leguellec K, Philippe M, Roberts JM: Human cyclin E: A new cyclin that interacts with two members of the CDC2 gene family. Cell 66: 1217-1228, 1991
23. 1 cyclin-dependent kinases. Genes Dev 9: 1149-1163, 1995
24. 1 cyclin (Cln) function in yeast. Cell 66: 1197-1206, 1991
25. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707, 1993
26. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 81: 323-330, 1995
27. Lundberg AS, Weinberg RA: Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol 18: 753-761, 1998
28. Matsushime H, Roussel MF, Ashnun RA, Sherr CJ: Colony-stimulation factor 1 regulates novel cyclins during the G 1 phase of the cell cycle. Cell 65: 701-713, 1991
29. Ewen ME, Sluss HK, Whitehouse LL, Livingston DM: TGF-β inhibition of Cdk4 synthesis is linked to cell cycle arrest. Cell 74: 1009-1020, 1993
30. 1 cyclins and cyclin-dependent protein kinases. Proc Natl Acad Sci USA 90: 10315-10319, 1993
31. INK4b is a potential effector cell cycle arrest mediated by TGF-β. Nature 371: 257-261, 1994
32. NK4/MTS2 related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev 8: 2939-2952, 1994
33. Hirai H, Roussel MF, Kato J, Ashmun RA, Sherr CJ: Novel INK4 proteins, p19 and p18, are specific inhibitors of cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol 15: 2672-2681, 1995
34. Kipl a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78: 59-66, 1994
35. 1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78: 67-74, 1994
36. El-Deiry WS, Tokino T, Velculescu VE, Levi DB, Parsons R, Trent JM, Lin D, Mercer E, Kinzler KW, Vogelstein B: WAFI, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993
37. Gu Y, Turck CW, Morgan DO: Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 366: 707-710, 1993
38. 1 cyclin-dependent kinases. Cell 75: 805-816, 1993
39. KIP2 a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 9: 639-69, 1995
40. 1 in rat fibroblasts causes abnormalities in growth control. cell cycle progression and gene expression. Oncogene 8:3447-3457, 1993
41. Quelle DE, Ashmun RA, Shurtleff SA, Kato JY, Bar-Sagi D, Roussel MF and Sherr CJ: Overexpression of mouse D-type cyclins accelerates Gl phase in rodent fibroblasts. Gene Dev 7: 1559-1571, 1993
42. Han EKH, Sgambato A, Jiang W, Zhang Y-J, Santella RM, Doki Y, Cacace AM, Schieren I, Weinstein B: Stable overexpression of cyclin D1 in a human mammary epithelial cell line prolongs the S-phase and inhibits growth. Oncogene 10: 953-961, 1995
43. Kraneburg O, Van der Eb A, Zantema A: Cyclin D1 is an essential mediator of apoptotic neuronal cell death. EMBO J 15: 46-54, 1996
44. Soule H, Maloney TM, Wolman SR, Peterson WD, Brenz R, McGrath CM, Russo J, Pauley RJ, Jones RF, Brooks SC: Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 50: 6075-6086, 1990
45. Mahaffey DT, Yoo Y, Rechsteiner M: Ubiquitination of full-length cyclin. FEBS Letters 370: 109-112, 1995
46. Pagano M, Tam SW, Therodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PW, Draetta GF, Rolfe M: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science (Washington DC) 269:682-685, 1995
47. Chou JL, Rozmahel R, Tsui L-C: Characterization of the promoter region of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. J Biol Chem 266: 24471-24476, 1990
48. Chou JL, Shen ZX, Stolfi RL, Martin DS, Waxman S: Effects of extracellular matrix on the growth and casein gene expression of primary mouse mammary tumor cells in vitro. Cancer Res 49: 5371-5376, 1989
49. INK4B-cdk4 complexes, and inhibits cyclin D1-cdk4 association in human mammary epithelial cells. Mol Cell Biol 17: 2458-2467 1997
50. Kim TK, Ravitz MJ, Wenner CE: Transforming growth factor-beta regulation of retinoblastoma gene product and E2F transcription factor during cell cycle progression in mouse fibroblasts. J Cell Physiol 160: 1-9, 1994
51. KIPI, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev 8: 9-22, 1994
52. KIPI. Mol Cell Biol 17: 3850-3857, 1997
53. Diehl JA, Zindy F, Sherr CJ: Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Gene Dev 11:957-972, 1997
54. Choi YH, Lee SJ, Nguyen P, Jang JS, Lee J, Wu M-L, Takano E, Maki M, Henkart PA, Trepel JB: Regulation of cyclin D1 by calpain protease. J Biol Chem 272: 28479-28484, 1997
55. Lammie GA, Fantl V, Smith R, Schuring E, Brookes S, Michalides R, Dickson C, Arnold A, Peters G: D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene 6:439-444, 1991
56. Buckley MF, Sweeney KJE, Hamilton JA, Sini RL, Manning DL, Nicholson RJ, de Fazio A, Watts CK, Musgrove EA, Sutherland RL: Expression and amplification of cyclin genes in human breast cancer. Oncogene 8:2127-2133, 1993
57. Jiang W, Kahan N, Tomita N, Zhang Y, Lu S, Weinstein IB: Amplification and expression of the human cyclin D gene in esophageal cancer. Cancer Res 52:2980-2983, 1992
58. Berenson JR, Yang J, Mickel RA: Frequent amplification of bcl-1 locus in head and neck squamous cell carcinomas. Oncogene 4: 1111-1116, 1989
59. Callender T, El-Nagger AK, Lee MS, Frankenhaler R, Luna MA, Batsakis JG: PRAD-1 (CND1)/cyclin D1 oncogene amplification in primary head and neck squamous cell carcinoma. Cancer (Philadelphia) 74: 152-158, 1994
60. Lucas JM, Mountain RE, Gramza AW, Schuller DE, Wikie NM, Lang JC: Expression of cyclin D1 in squamous cell carcinomas of the head and neck. Int J Oncol 5: 469-472, 1994
61. Rosenberg CL, Wong E, Petty EM, Bale AAE, Tsujimoto Y, Harris NL, Arnold A: PRAD1, a candidate BCL-I oncogene: Mapping and expression in centrocytic lymphoma. Proc Natl Acad Sci USA 88: 9638-9642, 1991
62. Withers DA, Harvey RC, Faust JB, Melnk O, Carey K, Meeker TC: Characterization of a candidate bcl-1 gene. Mol Cell Biol 11:4846-4853, 1991
63. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV: Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369:669-671, 1994
64. Mueller A, Odze R, Jenkios TD, Shahsesfaei A, Inomoto T, Rustgi AK: A transgenic mouse model with cyclin D1 overexpression results in cell cycle, epidermal growth factor receptor, and p53 abnormalities. Cancer Res 57:5542-5549, 1997
65. Lovec H, Grzeschiczek A, Kowalski MB, Moroy T: Cyclin D1/bcl1 cooperates with myc genes in the generation of B cell lymphoma in transgenic mice. EMBO J 13: 3487-3495, 1994
66. Hinds PW, Dowdy SF, Eaton EN, Arnold A, Winberg RA: Function of a human cyclin genes as an oncogene. Proc Natl Acad Sci USA 91: 709-713, 1994
67. 1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene 12: 1397-1403, 1996
68. KIPI and induces G1 arrest in prostate cancer cell line DU145. Cancer Res 56: 3666-3669, 1996
69. KipI accumulation during the cell cycle. Science( Washington DC) 271: 1861-1864, 1996
70. 1 in mammalian cells: Inhibition of cyclin E-dependent kinase by TGF-β. Science (Washington DC) 260: 536-539, 1993
71. Peeper DS, Upton TM, Ladha MH, Neuman E, Zalvide J, Bernards R, DeCaprio JA, Ewen ME: Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein. Nature 386: 177-181, 1997
72. Weber JD, Hu W, Jefcoat SC, Raben DM, Balassare JJ: Ras-stimulated extracellular signal-related kinase I and RhoA activities coordinate platelet-derived growth factor-induced G1 progression through the independent regulation of cyclin D1 and p27. J Biol Chem 272: 32966-32971, 1997